600216 浙江醫藥
按盤價 
10.610 -0.290 (-2.661%) | 2026/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 6,246,063 | -6.71% | 8,880,602 | 9,375,217 | 7,794,146 | 8,115,805 | |
| 減：營業總成本 | 5,595,034 | -0.76% | 7,817,213 | 7,934,024 | 7,681,666 | 7,482,025 | |
| 其中:營業成本 | 4,044,573 | -3.35% | 5,801,864 | 5,406,541 | 5,269,879 | 5,318,274 | |
| 財務費用 | 93,607 | -200.37% | (72,972) | (4,958) | (17,488) | (37,966) | |
| 資產減值損失 | (70,417) | -25.26% | (202,120) | (263,899) | (137,208) | (117,141) | |
| 公允價值變動收益 | (8,648) | -140.48% | 4,642 | (21,534) | (10,099) | (23,881) | |
| 投資收益 | 58,106 | 983.08% | 2,580 | (8,069) | (3,505) | (32,626) | |
| 其中：對聯營企業和合營企業的投資收益 | (6,605) | -1.94% | (9,347) | (9,643) | (9,782) | (3,806) | |
| 營業利潤 | 677,714 | -35.35% | 962,930 | 1,223,110 | 380,158 | 504,616 | |
| 利潤總額 | 666,013 | -36.35% | 951,729 | 1,212,282 | 363,279 | 491,388 | |
| 減：所得稅費用 | 115,455 | -35.71% | 191,490 | 192,031 | 86,485 | 128,775 | |
| 淨利潤 | 550,557 | -36.48% | 760,239 | 1,020,252 | 276,794 | 362,614 | |
| 減：非控股權益 | (142,244) | 114.17% | (113,141) | (140,259) | (152,845) | (176,956) | |
| 股東淨利潤 | 692,801 | -25.76% | 873,380 | 1,160,511 | 429,640 | 539,570 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.720 | -25.77% | 0.910 | 1.210 | 0.450 | 0.560 | |
| 每股派息 (元) * | -- | -- | 0.280 | 0.370 | 0.150 | 0.170 | |
| 每股淨資產 (元) * | 11.950 | 3.95% | 11.380 | 11.073 | 9.980 | 9.594 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 29/10/2026 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
